Current and emerging treatments for uterine myoma - An update

International Journal of Women's Health

Volumn 3, Issue 1, 2011, Pages 231-242

  Duhan, Nirmala ^a  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Gnrh; Hysterectomy; Leiomyoma; Myomectomy; Pelvic tumor; Uterine artery embolization

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFIBRINOLYTIC AGENT; AROMATASE INHIBITOR; ASOPRISNIL; DANAZOL; GESTAGEN; GONADORELIN; IBUPROFEN; LEVONORGESTREL; MIFEPRISTONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; ULIPRISTAL;

ACNE; ANEMIA; ARTIFICIAL EMBOLISM; BREAST ATROPHY; CONSERVATIVE TREATMENT; DEEP VEIN THROMBOSIS; DYSMENORRHEA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HOT FLUSH; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; IRRITABILITY; LAPAROSCOPY; MENORRHAGIA; MENSTRUATION DISORDER; MUSCULOSKELETAL PAIN; MYOMA; MYOMECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE PERIOD; REASSURANCE; REVIEW; ROBOTICS; SIDE EFFECT; STOMACH ULCER; SURGICAL RISK; SURGICAL TECHNIQUE; SYMPTOMATOLOGY; UTERINE ARTERY; UTERUS MYOMA; WEIGHT GAIN;

EID: 84055207470     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/ijwh.s15710     Document Type: Review

References (59)

1. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol. 2002;99:229-234.
2. Guarnaccia MM, Rein MS. Traditional surgical approaches to uterine fibroids: abdominal myomectomy and hysterectomy. Clin Obstet Gynecol. 2001;44(2);385-400.
3. Myers ER, Barber MW, Couchman GM, et al. Management of uterine fbroids. Evidence Report/Technology Assessment No. 34. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-97-0014.) AHRQ Publication 01-E052. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
4. Duhan N, Sirohriwal D. Uterine myomas revisited. Eur J Obstet Gynecol Reprod Biol. 2010;152:119-125.
5. Piscitelli JT, Simel DL, Addison WA. Who should have intravenous pyelogram before hysterectomy for benign disease? Obstet Gynecol. 1987;69:541-545.
6. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008;112(2 Pt 1):387-400.
7. Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-infammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med. 2002;69:S131-S139.
8. Eisinger SH, Meldrum S, Fiscella K, Le Roux HD, Guzick DS. Low dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101: 243-250.
9. Wilkens J, Chwalisz K, Han C, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood fow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab. 2008;93(12): 4664-4671.
10. Morikawa A, Ohara N, Xu Q, et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod. 2008;23(4): 944-951.
11. Ke LQ, Yang K, Li C-M, Li J. Danazol for uterine fbroids. Cochrane Database Syst Rev. 2009;(3):CD007692.
12. Jindabanjerd K, Taneepanichskul S. The use of levonorgestrel-IUD in the treatment of uterine myoma in Thai women. J Med Assoc Thai. 2006;89(4):5147-5151.
13. Murat Naki M, Tekcan C, Ozcan N, Cebi M. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menor-rhagia among women of reproductive age without a signifcant regression in the uterine and leiomyoma volumes. Fertil Steril. 2010;94(1): 371-374.
14. Golan A. GnRH analogues in the treatment of uterine fbroids. Hum Reprod. 1996;11:33-41.
15. DeFalco M, Staibano S, Mascolo M, et al. Leiomyoma pseudocapsule after presurgical treatment with gonadotropin releasing hormone agonists: relationship between clinical features and immunohistochemical changes. Eur J Obstet Gynecol Reprod Biol. 2009;144:44-47.
16. Crosignani PG, Vercellini P, Meschia M, Oldani S, Bramante T. GnRH agonists before surgery for uterine biomyomas: a review. J Reprod Med. 1996;41:415-421.
17. De Leo V, Morgante G, Lanzetta D, D'Antona D, Bertieri RS. Danazol administration after gonadotropin-releasing hormone analogue reduces rebound of uterine myomas. Hum Reprod. 1997:12(2):357-360.
18. Lethaby A, Vollenhoven B, Sowter MC. Preoperative GnRH analogue therapy before hysterectomy or myomectomy for uterine fbroids. Cochrane Database Syst Rev. 2001(2):CD000547.
19. Carranza LS. Relation between hormonal therapy and tibolone with SERMs in postmenopausal women's myomas growth. Ginecol Obstet Mex. 2008;76(10):610-614.
20. Palomba S, Orio F Jr, Falbo A, Oppedisano R, Tolini A, Zullo F. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas. Fertil Steril. 2008;90(1): 165-173.
21. Karaer O, Oru A, Koyuncu FM. Aromatase inhibitors: possible future applications. Acta Obstet Gynecol Scand. 2004;83(8):699-706.
22. Varelas FK, Papanicolaou AN, Vatvatsi N, Makidos GA, Vlassis GD. The effect of anastrazole on symptomatic uterine leiomyomata. Obstet Gynecol. 2007;110(3):643-649.
23. Mohammed EA, Mina A, Saeed A, et al. A randomized controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;74(1): 192-198.
24. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod. 2003;18:61-68.
25. Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Ye n SS. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril. 1996;65(1):23-28.
26. Engman M, Granberg S, Williams ARW, Meng CX, Lalit Kumar PGL, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009;24(8):1870-1879.
27. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol. 2008;111(5):1129-1136.
28. Terzic M. Focused ultrasound for treatment of uterine myoma: from experimental model to clinical practice. Srp Arh Celok Lek. 2008;136: 193-195.
29. De Melo FC, Dicoyannis L, Moll A, Tovar-Moll F. Reduction by 98% in uterine myoma volume associated with signifcant symptom relief after peripheral treatment with magnetic resonance imaging-guided focused ultrasound surgery. J Minim Invasive Gynecol. 2009:16:501-503.
30. Lenard ZM, McDannold NJ, Fennessy FM, et al. Uterine leiomyomas: MR imaging-guided focused ultrasound surgery-imaging predictors of success. Radiologia. 2008;249(1):187-194.
31. Funaki K, Fukunishi H, Funaki T, Sawada K, Kaji V, Maruo T. Magnetic resonance-guided focused ultrasound surgery for uterine fbroids: relationship between the therapeutic effects and signal intensity of preexisting T2-weighted magnetic resonance images. Am J Obstet Gynecol. 2007;196(2):184.e1-e6.
32. Smart OC, Hindley JT, Regan L, Gedroyc WG. Gonadotrophin releasing hormone and magnetic resonance guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol. 2006;108(1):49-54.
33. Smart OC, Hindley JT, Regan L, Gedroye WM. Magnetic resonance guided focused ultrasound surgery of uterine fbroids- the tissue effects of GnRH agonist pretreatment. Eur J Radiol. 2006;59(2):163-167.
34. Yoon S.W, Lee C, Cha SH, et al. Patient selection guidelines in MR-guided focused ultrasound surgery of uterine fbroids: a pictorial guide to relevant fndings in screening pelvic MRI. Eur Radiol. 2008;18(12):2997-3006.
35. Stewart EA, Robinovici J, Tempany CMC, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fbroids. Fertil Steril. 2006;85(1):22-29.
36. Zowall H, Cairns JA, Brewer C, Lamping DL, Gedroyc WMW, Regan L. Cost effectiveness of mangnetic resonance-guided focused ultrasound surgery for treatment of uterine fbroids. BJOG. 2008;115(5):653-662.
37. Goodwin SC, Spies JB, Worthington-Kirsch R, et al. Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol. 2008;111(1):22-33.
38. Hurst BS, Stackhouse DJ, Mathews ML, Marshburn PB. Uterine artery embolization for symptomatic uterine myomas. Fertil Steril. 2000:74:855-869.
39. Ravina JH, Vigneron NC, Aymard A, Le Dref O, Merland J. Pregnancy after embolization of uterine myoma: report of 12 cases. Fertil Steril. 2000;73:1241-1243.
40. Hirst A, Dutton S, Glu O, et al. A multi-centre retrospective cohort study comparing the effcacy, safety and cost effectiveness of hysterectomy and uterine artery embolization for the treatment of symptomatic uterine fbroids. The HOPEFUL study. Health Technol Assess. 2008;12(5):1-248, iii.
41. Gupta JK, Sinha A, Lumsden MA, Hickey M. Uterine artery embiliza-tion for symptomatic uterine fbroids. Cochrane Database Syst Rev. 2006(1):CD005073.
42. Lefebvre G, Vilos G, Allairi C, et al. The management of uterine leiomyomas. J Obstet Gynecol. 2003;25:395-418.
43. Jin C, Hu Y, Chen XC, Zheng FY, Lin F, Zhou K, et al. Laparoscopic versus open myomectomy - a meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2009;145:14-21.
44. Kongnyuy FJ, Wiysonge CS. Interventions to reduce hemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev. 2009;(3):CD005355.
45. Duhan N, Rajotia N, Duhan H, Sangwan N, Gulati N, Sirohiwal D. Isthmic uterine fbroids: the dynamics of growth. Arch Gynecol Obstet. 2009;280:309-312.
46. Sawin SW, Pilevsky ND, Berlin JA, Barnhart NT. Comparability of perioperative morbidity between abdominal myomectomy and hysterectomy for women with uterine leiomyomas. Am J Obstet Gynecol. 2000;183:1448-1455.
47. Cohen IS, Valle RF. Role of vaginal sonography and hysterosonog-raphy in endoscopic treatment of uterine myomas. Fertil Steril. 2000;73:197-204.
48. Morita M, Asakawa Y. Reproductive outcome after laparoscopic myomectomy for intramural myomas in infertile women with or without associated infertility factors. Reprod Med Biol. 2008;5: 31-35.
49. Harkki SP, Sjoberg J, Tiitinen A. Urinary tract injuries after hysterectomy. Obstet Gynecol. 1998:92:113-118.
50. Thakar R, Ayers S, Clarkson P, Stanton S, Manyonda L. Outcomes after total versus subtotal abdominal hysterectomy. N Engl J Med. 2002;347:1318-1325.
51. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988-1990. Obstet Gynecol. 1994:83:549-555.
52. Goldfarb HA. Myoma coagulation (myolysis). Obstet Gynecol Clin North Am. 2000:27:421-430.
53. Cowan BD, Sewell PE, Howard JC, Arriola RM, Robinette LG. Interventional magnetic resonance imaging cryotherapy of uterine fbroid tumors: preliminary observation. Am J Obstet Gynecol. 2002; 186:1183-1187.
54. Akinola OI, Fabamwo AO, Ottun AT, Akinniyi OA. Uterine artery ligation for management of uterine fbroids. Int J Gynecol Obstet. 2005;91(2):137-140.
55. Hald K, Noreng HJR, Istre O, Klow NE. Uterine artery embolization versus laparoscopic occlusion of uterine arteries for leiomyomas: long term results of a randomized comparative trial. J Vasc Intern Radiol. 2009;20(10):1303-1310.
56. Liu L, Li Y, Xu H, Chen Y, Zhang G, Liang Z. Laparoscopic transient uterine artery occlusion and myomectomy for symptomatic uterine myoma. Fertil Steril. 2011;95(1):254-258.
57. Liu WM, Wang PH, Tang WL, Wang IT, Tzeng CR. Uterine artery ligation for treatment of pregnant women with uterine leiomyomas who are undergoing cesarean section. Fertil Steril. 2006;86(2):423-428.
58. Lee WL, Liu WM, Fuh JL, Tsai YC, Shih CC, Wang PH. Use of uterine vessel occlusion in the management of uterine myomas: two different approaches. Fertil Steril. 2010;94(5):1875-1881.
59. Lee WL, Liu WM, Fuh JL, Tsai YC, Shih CC, Wang PH. Basal FSH level changes after different types of uterine vessel occlusion in the management of uterine fbroids. Fertil Steril. 2010;94(6):2286-2290.